The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Abstract
PURPOSE: This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin. PATIENTS AND METHODS: Between December 1987 and July 1990, 279 patients with histologically confirmed sarcomas were enrolled to receive treatment A (doxorubicin 80 mg/m2), treatment B (ifosfamide 7.5 g/m2 plus doxorubicin 60 mg/m2), or treatment C (mitomycin 8 mg/m2 plus doxorubicin 40 mg/m2 plus cisplatin 60 mg/m2). RESULTS: Of 262 assessable patients, 74 (29%) achieved objective tumor regression. Objective regression occurred in 20% of the 90 patients who received doxorubicin alone (complete remission [CR] rate, 2%), in 34% of the 88 who received ifosfamide plus doxorubicin (CR rate, 3%), and in 32% of the 84 who received mitomycin plus doxorubicin plus cisplatin (CR rate, 7%). With grade 3 or greater myelosuppression in 53% of group A, 80% of group B, and 55% of group C, regimen B was significantly more myelosuppressive than either regimen A or C (P = .01) with two, three, and one treatment-related deaths, respectively. Synovial sarcomas were responsive to ifosfamide plus doxorubicin, especially among patients younger than 40 years of age. CONCLUSION: Ifosfamide plus doxorubicin produced a significantly higher regression rate (P = .03) than did doxorubicin alone; however, this was achieved at a level of myelosuppression significantly more intense than that produced by the single agent or by the three-drug combination. Mitomycin, doxorubicin, and cisplatin also appeared to be more active than the single agent; however, at a myelosuppression level similar to that of doxorubicin alone, this trend (P = .07) did not attain the usual level for significance. No significant survival differences were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1989) · PubMed · Cited by 3,343
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Antman, K. H., Crowley, J. J., Balcerzak, S. P., Rivkin, S. E., Weiss, G. R., ELIAS, A. D., Natale, R. B., Cooper, R. M., Barlogie, B., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1276 · Cited by 478
Phase II evaluation of adriamycin in human neoplasia
O'Bryan, R. M., Luce, J. K., Talley, R. W., Gottlieb, J. A., Baker, L. H., & Bonadonna, G. (1973) · Cancer · doi:10.1002/1097-0142(197307)32:1<1::aid-cncr2820320101>3.0.co;2-x · Cited by 418
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
Borden, E. C., Amato, D. A., Rosenbaum, C., Enterline, H. T., Shiraki, M. J., Creech, R. H., Lerner, H. J., & Carbone, P. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.840 · Cited by 299
Self-citationPhase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
Antman, K. H., Montella, D., Rosenbaum, C., & Schwen, M. (1985) · PubMed · Cited by 87
Drug Resistance in Chinese Hamster Ovary Cells During Recovery From Severe Hypoxia
Wilson, R. E., Keng, P. C., & Sutherland, R. M. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.16.1235 · Cited by 75
Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.
Loehrer, P. J., Sledge, G. W., Nicaise, C., Usakewicz, J., Hainsworth, J. D., Martelo, O. J., Omura, G., & Braun, T. J. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1655 · Cited by 61
Rockwell, S., Kennedy, K. A., & Sartorelli, A. C. (1982) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(82)90728-3 · Cited by 59
Bezwoda, W. R., Derman, D. P., de Moor, N. G., Lange, M., & Levin, J. (1982) · Cancer · doi:10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co;2-j · Cited by 35
Cited by
Pervaiz, N., Colterjohn, N., Farrokhyar, F., Tozer, R., Figueredo, A., & Ghert, M. (2008) · Cancer · doi:10.1002/cncr.23592 · Cited by 987
Garcia-Carbonero, R., Supko, J. G., Manola, J., Seiden, M. V., Harmon, D., Ryan, D. P., Quigley, M. T., Merriam, P., Canniff, J., Goss, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.098 · Cited by 294
Lorigan, P., Verweij, J., Papai, Z., Rodenhuis, S., Le Cesne, A., Leahy, M. G., Radford, J. A., Van Glabbeke, M. M., Kirkpatrick, A., Hogendoorn, P. C. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7717 · Cited by 256
Sutton, G., Brunetto, V. L., Kilgore, L., Soper, J. T., McGehee, R., Olt, G., Lentz, S. S., Sorosky, J., & Hsiu, J.-G. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.6001 · Cited by 254
Metadata
- Authors
- Edmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S., & Parkinson, D. R.
- Venue
- Journal of Clinical Oncology
- Published
- 1993-07
- Volume
- 11
- Issue
- 7
- Pages
- 1269-1275
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1892579032
- Cited by
- 516
- References
- 11
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. https://app.cochat.ai/papers/10.1200/jco.1993.11.7.1269
- The paper
- Edmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S., & Parkinson, D. R. (1993). Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1993.11.7.1269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
